Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC.

Brockwell NK, Rautela J, Owen KL, Gearing LJ, Deb S, Harvey K, Spurling A, Zanker D, Chan CL, Cumming HE, Deng N, Zakhour JM, Duivenvoorden HM, Robinson T, Harris M, White M, Fox J, Ooi C, Kumar B, Thomson J, Potasz N, Swarbrick A, Hertzog PJ, Molloy TJ, Toole SO, Ganju V, Parker BS.

NPJ Precis Oncol. 2019 Aug 29;3:21. doi: 10.1038/s41698-019-0093-2. eCollection 2019.

2.

Bifluoride Ion Mediated SuFEx Trifluoromethylation of Sulfonyl Fluorides and Iminosulfur Oxydifluorides.

Smedley CJ, Zheng Q, Gao B, Li S, Molino A, Duivenvoorden HM, Parker BS, Wilson DJD, Sharpless KB, Moses JE.

Angew Chem Int Ed Engl. 2019 Mar 26;58(14):4552-4556. doi: 10.1002/anie.201813761. Epub 2019 Feb 27.

PMID:
30740848
3.

Discriminating the earliest stages of mammary carcinoma using myoepithelial and proliferative markers.

Duivenvoorden HM, Spurling A, O'Toole SA, Parker BS.

PLoS One. 2018 Jul 25;13(7):e0201370. doi: 10.1371/journal.pone.0201370. eCollection 2018.

4.

Sustainable Syntheses of (-)-Jerantinines A & E and Structural Characterisation of the Jerantinine-Tubulin Complex at the Colchicine Binding Site.

Smedley CJ, Stanley PA, Qazzaz ME, Prota AE, Olieric N, Collins H, Eastman H, Barrow AS, Lim KH, Kam TS, Smith BJ, Duivenvoorden HM, Parker BS, Bradshaw TD, Steinmetz MO, Moses JE.

Sci Rep. 2018 Jul 13;8(1):10617. doi: 10.1038/s41598-018-28880-2.

5.

Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.

Duivenvoorden HM, Rautela J, Edgington-Mitchell LE, Spurling A, Greening DW, Nowell CJ, Molloy TJ, Robbins E, Brockwell NK, Lee CS, Chen M, Holliday A, Selinger CI, Hu M, Britt KL, Stroud DA, Bogyo M, Möller A, Polyak K, Sloane BF, O'Toole SA, Parker BS.

J Pathol. 2017 Dec;243(4):496-509. doi: 10.1002/path.4990. Epub 2017 Oct 31.

PMID:
29086922
6.

Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.

Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS.

Cancer Immunol Res. 2017 Oct;5(10):871-884. doi: 10.1158/2326-6066.CIR-17-0150. Epub 2017 Aug 28.

7.

The Dicentric Chromosome dic(20;22) Is a Recurrent Abnormality in Myelodysplastic Syndromes and Is a Product of Telomere Fusion.

MacKinnon RN, Duivenvoorden HM, Campbell LJ, Wall M.

Cytogenet Genome Res. 2016;150(3-4):262-272. doi: 10.1159/000456677. Epub 2017 Mar 4.

PMID:
28259884
8.

Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer.

Edgington-Mitchell LE, Rautela J, Duivenvoorden HM, Jayatilleke KM, van der Linden WA, Verdoes M, Bogyo M, Parker BS.

Oncotarget. 2015 Sep 29;6(29):27008-22. doi: 10.18632/oncotarget.4714.

9.

Unbalanced translocations of 20q in AML and MDS often involve interstitial rather than terminal deletions of 20q.

MacKinnon RN, Duivenvoorden HM, Campbell LJ.

Cancer Genet. 2011 Mar;204(3):153-61. doi: 10.1016/j.cancergen.2010.12.001.

PMID:
21504715

Supplemental Content

Loading ...
Support Center